Followers | 838 |
Posts | 22636 |
Boards Moderated | 1 |
Alias Born | 01/14/2012 |
Tuesday, October 21, 2014 8:35:56 PM
The genomic sequence of the Ebola virus responsible for the current outbreak in West Africa has been determined from several viral isolates. The Company has completed the design of a modified RNAi therapeutic specifically targeting this viral variant, now termed 'Ebola-Guinea.' The ability to rapidly and accurately match the evolving genetic sequences of emerging infectious agents is one of the powerful features of RNAi therapeutics.
In September, we announced our active engagement with an International Consortium led by the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), the University of Oxford, with representatives from the WHO, the US Centre for Disease Control (CDC), Medecins Sans Frontieres (MSF), Institut Pasteur and others, on plans for potential expedited clinical trials in West Africa. The Wellcome Trust has awarded [Pounds]3.2 million to the International Consortium to fund this initiative. The award includes funds for the manufacture of investigational therapeutics and to establish an operational clinical trials platform in two or more Ebola Virus Disease (EVD) treatment centers in West Africa. In this initiative, RNAi has been prioritized as a possible investigational therapeutic. However the use of our new product has not yet been confirmed.
As stated previously, the FDA authorized the Company to provide TKM-Ebola for treatment under expanded access protocols to patients with confirmed or suspected Ebola virus infections. The current supply of TKM-Ebola inventory is limited. However, Tekmira intends to continue to provide TKM-Ebola, if requested, to patients with confirmed or suspected Ebola virus infections under this regulatory framework. To date, several patients have been treated with the product and data collected will be provided to the FDA under the Company's Investigational New Drug Application (IND). We have established a similar framework with Health Canada for the potential use of TKM-Ebola for patients with confirmed or suspected Ebola virus infections.
The Company's IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects. We expect this matter to be resolved this quarter
http://investorshub.advfn.com/MAKE-IT-RAIN-(MIR)-25388/
MAKE IT RAIN BOARD WANTS YOU! SIGN UP FOR
OUR CALLS BASED ON TECHNICAL ANALYSIS
Recent ABUS News
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:38:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:31:16 PM
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:09:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/21/2023 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:39 PM
- Arbutus to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:18:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:16 PM
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:16:12 PM
- Arbutus Announces CEO, William Collier, to Retire December 31, 2023 • GlobeNewswire Inc. • 11/07/2023 12:15:00 PM
- Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 10/24/2023 11:30:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM